A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer

BACKGROUND: BTH1677, a beta-glucan pathogen-associated molecular pattern molecule, drives an anti-cancer immune response in combination with oncology antibody therapies. This phase II study explored the efficacy, pharmacokinetics (PK), and safety of BTH1677 combined with bevacizumab/carboplatin/pacl...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Engel-Riedel, Walburga, Lowe, Jamie, Mattson, Paulette, Richard Trout, J., Huhn, Richard D., Gargano, Michele, Patchen, Myra L., Walsh, Richard, Trinh, My My, Dupuis, Mariève, Schneller, Folker
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5830087/
https://ncbi.nlm.nih.gov/pubmed/29486797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0324-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky